Hector Ivan Saldivar Ceron

Dr. Hector Ivan Saldivar Ceron

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
RSRicardo Xopan Suárez-García
Ricardo Xopan Suárez-García
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RORodrigo Orrico-Pérez
Rodrigo Orrico-Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
DIALOGUE (DIagnostic AI Learning through Objective Guided User Experience) is a generative artificial intelligence (GenAI)-based training program designed to enhance diagnostic communication skills in medical students. In this single-arm pre–post study, we evaluated whether DIALOGUE could improve students’ ability to disclose a type 2 diabetes mellitus (T2DM) diagnosis with clarity, structure, and empathy. Thirty clinical-phase students completed two pre-test virtual encounters with an AI-simulated patient (ChatGPT, GPT-4o), scored by blinded raters using an eight-domain rubric. Participants then engaged in ten asynchronous GenAI scenarios with automated natural-language feedback. Seven days later, they completed two post-test consultations with human standardized patients, again evaluated with the same rubric. Mean total performance increased by 36.7 points (95% CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0% to 70%. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes specific explanation. Multiple regression showed that lower baseline empathy (β = −0.41, p = 0.005) and higher digital self-efficacy (β = 0.35, p = 0.016) independently predicted greater improvement; gender had only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain group characterized by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated training can meaningfully enhance diagnostic communication and may serve as a scalable, individualized adjunct to conventional medical education.

11 June 2025 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
JVJorge Arturo Vargas-Camacho
Jorge Arturo Vargas-Camacho
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
PDPaola Briseño Diaz
Paola Briseño Diaz
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
MDMaría Regina Díaz-Domínguez
María Regina Díaz-Domínguez
Small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent an innovative advancement in oral therapeutics, addressing key limitations associated with injectable peptide-based incretin therapies. These nonpeptidic agents exert their actions primarily through non-canonical binding orthosteric sites within the GLP-1 receptor transmembrane domain, enabling selective G protein (Gs)-biased signaling with reduced β-arrestin-mediated adverse effects. Orforglipron has notably advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability. Conversely, promising candidates such as danuglipron and lotiglipron were discontinued due to hepatotoxicity, underscoring critical safety concerns intrinsic to small-molecule GLP-1RA development. Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, continue to offer substantial potential due to their oral bioavailability, simplified dosing regimens, and favorable gastrointestinal tolerability. Nevertheless, challenges persist regarding hepatic safety, pharmacodynamic variability, and limited long-term outcome data. This review integrates current structural, pharmacological, and clinical evidence, highlights key mechanistic innovations—including biased agonism, covalent binding strategies, and allosteric modulation—and discusses future directions for this rapidly evolving therapeutic class in metabolic disease management.

Verified
Journal Article
Open access
PDF file
LÁLissuly Guadalupe Álvarez-Hilario
Lissuly Guadalupe Álvarez-Hilario
ESEric Genaro Salmerón
Eric Genaro Salmerón
PAPedro Avila
Pedro Avila
GHGeorgina Hernández-Montes
Georgina Hernández-Montes
EAElena Arechaga-Ocampo
Elena Arechaga-Ocampo
RHRosaura Hernández-Rivas
Rosaura Hernández-Rivas
Among malignant neoplasms, pancreatic ductal adenocarcinoma (PDAC) has one of the highest fatality rates due to its late detection. Therefore, it is essential to discover a noninvasive, early, specific, and sensitive diagnostic method. MicroRNAs (miRNAs) are attractive biomarkers because they are accessible, highly specific, and sensitive. It is crucial to find miRNAs that could be used as possible biomarkers because PDAC is the eighth most common cause of cancer death in Mexico. With the help of microRNA microarrays, differentially expressed miRNAs (DEmiRNAs) were found in PDAC tissues. The presence of these DEmiRNAs in the plasma of Mexican patients with PDAC was determined using RT-qPCR. Receiver operating characteristic curve analysis was performed to determine the diagnostic capacity of these DEmiRNAs. Gene Expression Omnibus datasets (GEO) were employed to verify our results. The Prisma V8 statistical analysis program was used. Four DEmiRNAs in plasma from PDAC patients and microarray tissues were found. Serum samples from patients with PDAC were used to validate their overexpression in GEO databases. We discovered a new panel of the two miRNAs miR-222-3p and miR-221-3p that could be used to diagnose PDAC, and when miR-221-3p and miR-222-3p were overexpressed, survival rates decreased. Therefore, miR-222-3p and miR-221-3p might be employed as noninvasive indicators for the diagnosis and survival of PDAC in Mexican patients.

28 November 2023 in Molecular and Cellular Biology
Verified
Journal Article
Open access
OVOlga Villamar-Cruz
Olga Villamar-Cruz
MLMarco A. Loza-Mejía
Marco A. Loza-Mejía
Alonso Vivar-SierraAlonso Vivar-Sierra
Alonso Vivar-Sierra
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
Genaro Patino-LopezGenaro Patino-Lopez
Genaro Patino-Lopez
LALuis E. Arias-Romero
Luis E. Arias-Romero
PTP1B plays a key role in developing different types of cancer. However, the molecular mechanism underlying this effect is unclear. To identify molecular targets of PTP1B that mediate its role in tumorigenesis, we undertook a SILAC-based phosphoproteomic approach, which allowed us to identify Cdk3 as a novel PTP1B substrate. Substrate trapping experiments and docking studies revealed stable interactions between the PTP1B catalytic domain and Cdk3. In addition, we observed that PTP1B dephosphorylates Cdk3 at tyrosine residue 15 in vitro and interacts with it in human glioblastoma cells. Next, we found that pharmacological inhibition of PTP1B or its depletion with siRNA leads to cell cycle arrest with diminished activity of Cdk3, hypophosphorylation of Rb, and the downregulation of E2F target genes Cdk1, Cyclin A, and Cyclin E1. Finally, we observed that the expression of a constitutively active Cdk3 mutant bypasses the requirement of PTP1B for cell cycle progression and expression of E2F target genes. These data delineate a novel signaling pathway from PTP1B to Cdk3 required for efficient cell cycle progression in an Rb-E2F dependent manner in human GB cells.

Verified
Journal Article
Open access
PDF file
CRCarlos Raúl Robledo-Millán
Carlos Raúl Robledo-Millán
MDMaría Regina Diaz-Domínguez
María Regina Diaz-Domínguez
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
EQEfrén Quiñones-Lara
Efrén Quiñones-Lara
SVSebastián Valencia-Marín
Sebastián Valencia-Marín
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
Background: As metabolic diseases continue to rise globally, there is a growing need to improve risk assessment strategies beyond traditional measures such as BMI and waist circumference, which may fail to identify individuals at risk. This study develops and validates a novel metabolic risk classification system that incorporates body fat percentage (%BF), waist circumference (WC), and grip strength (GS) in Mexican adults. It aims to improve risk stratification and evaluate the association with metabolic syndrome. Methods: This cross-sectional study involved 300 young adults (18–22 years) from a university in Mexico City, utilizing body composition (%BF) and anthropometric measures (WC, GS) to categorize them into four risk groups: protective, low risk, increased risk, and high risk. A retrospective cohort of 166 adults (18–65 years) with complete clinical records was used for validation. Results: The inclusion of GS in the risk assessment significantly shifted the distribution in the young adult cohort, reducing the “no risk” category (15.5% males, 11.6% females) and expanding the higher-risk categories (70.2% males, 69% females). Metabolic parameters such as fasting glucose, triglycerides, HDL cholesterol, and blood pressure worsened progressively across the risk categories (p < 0.001). The high-risk group exhibited a markedly increased odds ratio for metabolic syndrome at 28.23 (10.83–73.6, p < 0.001), with no cases in the protective and low-risk groups. Conclusions: Integrating grip strength with %BF and WC into a risk classification system substantially enhances metabolic risk stratification, identifies at-risk individuals not previously detected, and confirms a protective group. This validated system provides a robust tool for early detection and targeted interventions, improving public health outcomes in metabolic health.

10 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RGRicardo Xopan Suarez Garcia
Ricardo Xopan Suarez Garcia
QCQuetzal Chavez Castañeda
Quetzal Chavez Castañeda
RPRodrigo Orrico Pérez
Rodrigo Orrico Pérez
SVSebastián Valencia-Marin
Sebastián Valencia-Marin
ACAri Evelyn Castañeda-Ramírez
Ari Evelyn Castañeda-Ramírez
HCHector Ivan Saldivar Ceron
Hector Ivan Saldivar Ceron
Effective diagnostic communication—delivering a diagnosis with clarity, structure, and empathy—remains a challenging competency for many undergraduate medical students. This single-arm pre–post study evaluated a generative artificial-intelligence (GenAI) training module designed to improve diagnostic-communication performance. Thirty clinical-phase students completed two pre-test encounters in which they disclosed a type 2 diabetes mellitus (T2DM) diagnosis to a virtual patient powered by ChatGPT (GPT-4o) and were scored with an eight-domain rubric by blinded raters. They then undertook ten asynchronous GenAI scenarios with automated natural-language feedback, followed seven days later by two post-test consultations with human standardized patients assessed in real time with the same rubric. Mean total performance increased by 36.7 points (95 % CI: 31.4–42.1; p < 0.001), and the proportion of high-performing students rose from 0 % to 70 %. Gains were significant across all domains, most notably in opening the encounter, closure, and diabetes-specific explanation. Multiple regression showed that lower baseline empathy (β = –0.41, p= 0.005) and higher digital self-efficacy (β = 0.35, p= 0.016) inde-pendently predicted greater improvement; gender displayed only a marginal effect. Cluster analysis revealed three learner profiles, with the highest-gain cluster character-ised by low empathy and high digital self-efficacy. Inter-rater reliability was excellent (ICC ≈ 0.90). These findings provide empirical evidence that GenAI-mediated practice can produce meaningful, measurable enhancements in diagnostic-communication skills and may serve as a scalable, individualised adjunct to conventional clinical education.